DALLAS — According to an SEC filing, nanotechnology company Anterios has launched a $2.5 million equity offering by raising $750,000.
In February 2010 the company completed a $1.5 million raise, and in October of 2009, raised $5.17 million of a targeted $10 million.
Named in the filings were directors and investors Dr. Jonathan Edelson and Geoffrey W. Smith, New York-based Ascent BioMedical Ventures, and Carter Meyer, Dallas-based Scientific Health Development, Ltd.
Formed in 2006, Anterios uses nanotechnology to provide a delivery system to administer drugs and cosmetics. The company was formerly known as Encapsion Inc.
SEC filing: http://tinyurl.com/334llce
Dr. Jonathan Edelson
Dr. Jonathan Edelson is a Director at Anterios Inc. He is also a Venture Partner at Ascent BioMedical Ventures. He has been an active Founder and Chief Executive Officer of private and public medical technology companies since 1989. Dr. Edelson was the Co-Founder and Chief Executive Officer for Aureon Laboratories, Med-E-Systems and AHT Corporation, Physicians’ Online, Inc., and Medical Decision Resources, Inc. He has been a co-inventor of diverse molecular and information technologies and is a patent-holder. Previously, he was an internist and conducted clinical research at Harvard’s Brigham & Women’s Hospital. Dr. Edelson’s research has been published in several of the world’s leading medical journals. He holds a B.A., summa cum laude, from Yale University and a M.D., with honors, from the University of Chicago, Pritzker School of Medicine.
Carter Meyer is the Chief Executive Officer of Scientific Health Development, Ltd., an investment fund focusing on early stage investments in medical, healthcare, wellness and science companies and technologies. Prior to joining Scientific Health Development, Ltd., he was an attorney in private practice for over 12 years, most recently with the Dallas office of the Vinson & Elkins L.L.P. As an attorney, Mr. Meyer focused on commercial transactions with substantial experience buying, selling, financing and making investments in both public and private entities. Mr. Meyer also has significant international experience having lived and worked in Japan and China for over two years. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary’s University School of Law. In addition to being on the board of CureDM, Inc., Mr. Meyer is the on the board of Calisto Medical, Inc. (a company developing a non-invasive glucose monitoring device) and Garfield Industries, Inc. (a company designing and marketing various air purification products).
Geoffrey W. Smith
Geoff has been an active founder, manager, and investor in healthcare and technology companies since 1995. He currently serves on the Board of Directors of Azevan Pharmaceuticals, Biomerix Corporation, Anterios Inc., Metronome Therapeutics, TargAnox, Inc., and Vivasure Medical Limited and is a Board Observer for Cara Therapeutics.
Geoff is a Visiting Scholar at Rockefeller University where he founded and directs the Science & Economics Program and is a faculty member at the Center for Clinical and Translation Science. He is also a member of the Leadership Council of the Biomedical Research Institute at Brigham & Women’s Hospital. At the Mount Sinai School of Medicine, Geoff is a member of the External Advisory Committee for the Mount Sinai Institutes of Clinical & Translational Sciences and a member of the Graduate School of Biological Sciences Oversight Committee.
Earlier in his career, Geoff was a corporate attorney in New York City. Prior to receiving his law degree, he served as a Research Associate at Harvard Business School.
Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.